The multitargeted molecular docking results consistently demonstrated strong binding affinities between 3-1-BCMIYPPA and crucial target proteins implicated in lung cancer progression, including CDK2, SRC-2 domains of C-ABL, EGFR, and IGF-1R and the robust interactions suggest the compound can effectively modulate the activity of these proteins, play pivotal roles in lung cancer development and growth. Here, SRC is linked to lung cancer.